Philippe Lambin
Universiteit Maastricht

Last Updated On 10/11/2023 11:07:40 AM
This is a disclosure report of the user financial relationships with for-profit health care companies.
All relationships are considered compensated unless otherwise noted. Relationships are self-held unless otherwise noted.

Employment
Company: Maastricht University
Recipient: An Immediate Family Member

Leadership
Company: Convert Pharmaceuticals SA
Recipient: You

Stock and Other Ownership Interests
Company: LivingMed Biotech
Recipient: An Immediate Family Member
Company: Bactam srl (Non medical biotech on green energy)
Recipient: An Immediate Family Member
Company: Oncoradiomics SA
Recipient: You
Company: Convert Pharmaceuticals SA
Recipient: You
Company: LivingMed Biotech sprl
Recipient: You
Company: Comunicare Solutions SA
Recipient: You
Company: Bactam srl (Non medical biotech on green energy)
Recipient: You

Honoraria
No Relationships to Disclose

Consulting or Advisory Role
Company: BHV sprl
Recipient: You
Company: Institut Jules Bordet
Recipient: You
Company: Gilde Healthcare Partners
Recipient: You
Company: Roche
Recipient: You
Company: Bristol-Myers Squibb (BMS)
Recipient: You

Speakers' Bureau
No Relationships to Disclose

Research Funding
Company: LivingMed Biotech
Recipient: Your Institution
Company: Convert Pharmaceuticals
Recipient: Your Institution
Company: Bactam srl
Recipient: Your Institution
Company: Philogen
Recipient: Your Institution

Patents, Royalties, Other Intellectual Property
Please describe: Co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Oncoradiomics and one issue patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, three non-patentable invention (softwares) licensed to ptTheragnostic/DNAmito, Oncoradiomics and Health Innovation Ventures.
Recipient: Your Institution
Please describe: Two non-issues, non licensed patents on Deep Learning-Radiomics (N2024482, N2024889).
Recipient: Your Institution
Please describe: One patent on Lymphocytes Sparing Radiotherapy (N2024889), licensed to Varian medical (1/3 of the royalties for the inventors, 2/3 for the institution)
Recipient: Your Institution
Please describe: Patent: PRODRUGS AND MEDICAL USES THEREOF (WO/2019/229195)
Recipient: Your Institution

Expert Testimony
No Relationships to Disclose

Travel, Accommodations, Expenses
Company: Benelux Health Ventures
Recipient: You
Company: Roche
Recipient: You

Other Relationship
No Relationships to Disclose

(OPTIONAL) Uncompensated Relationships
Company: Institut of Cancer Research, UK
Recipient: You
Company: CRC UK Lung Cancer Center of Excellence
Recipient: You
Company: Exomnis Biotech (SAB, board member)
Recipient: You
Company: Health Innovation Ventures (CSA, board member)
Recipient: You
Company: LivingMed Biotech (CSA, board member)
Recipient: You
Company: Radiomics.bio (Oncoradiomics, CSA, board member)
Recipient: You
Company: Comunicare Solutions (CSA, board member)
Recipient: You
Company: BACTAM (Non medical biotech, CSA, board member)
Recipient: You

(OPTIONAL) Open Payments Link
No Relationships to Disclose